Malaysian Genomics Resource Centre Bhd (XKLS:0155) Cash-to-Debt : 1.79 (As of Sep. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Malaysian Genomics Resource Centre Bhd Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Malaysian Genomics Resource Centre Bhd's cash to debt ratio for the quarter that ended in Sep. 2023 was 1.79.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Malaysian Genomics Resource Centre Bhd could pay off its debt using the cash in hand for the quarter that ended in Sep. 2023.

The historical rank and industry rank for Malaysian Genomics Resource Centre Bhd's Cash-to-Debt or its related term are showing as below:

XKLS:0155' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.37 Med: 13.83 Max: No Debt
Current: 1.79

During the past 13 years, Malaysian Genomics Resource Centre Bhd's highest Cash to Debt Ratio was No Debt. The lowest was 0.37. And the median was 13.83.

XKLS:0155's Cash-to-Debt is ranked better than
54.63% of 216 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.295 vs XKLS:0155: 1.79

Malaysian Genomics Resource Centre Bhd Cash-to-Debt Historical Data

The historical data trend for Malaysian Genomics Resource Centre Bhd's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Malaysian Genomics Resource Centre Bhd Cash-to-Debt Chart

Malaysian Genomics Resource Centre Bhd Annual Data

Trend

Jun12

Jun13

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Cash-to-Debt

Get a 7-Day Free Trial

0.38

0.60

0.41

N/A

6.85

Malaysian Genomics Resource Centre Bhd Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23
Cash-to-Debt	Get a 7-Day Free Trial															12.63	5.11	2.40	2.65	1.79

Competitive Comparison of Malaysian Genomics Resource Centre Bhd's Cash-to-Debt

For the Diagnostics & Research subindustry, Malaysian Genomics Resource Centre Bhd's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Malaysian Genomics Resource Centre Bhd's Cash-to-Debt Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Malaysian Genomics Resource Centre Bhd's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Malaysian Genomics Resource Centre Bhd's Cash-to-Debt falls into.

Malaysian Genomics Resource Centre Bhd Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Malaysian Genomics Resource Centre Bhd's Cash to Debt Ratio for the fiscal year that ended in Jun. 2021 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	11.309	/	(0.348	+	1.302)
	=	6.85

Malaysian Genomics Resource Centre Bhd's Cash to Debt Ratio for the quarter that ended in Sep. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	3.685	/	(0.355	+	1.702)
	=	1.79

Malaysian Genomics Resource Centre Bhd (XKLS:0155) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Malaysian Genomics Resource Centre Bhd Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Malaysian Genomics Resource Centre Bhd's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Malaysian Genomics Resource Centre Bhd (XKLS:0155) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Malaysian Genomics Resource Centre Bhd (XKLS:0155) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

8F, Jalan Teknologi 3/6, Taman Sains, Petaling Jaya, SGR, MYS, 47810

Website

http://www.mgrc.com.my

Malaysian Genomics Resource Centre Bhd is a Malaysia-based company engaged in providing laboratory services. It primarily offers genome sequencing and analysis (GSA) services, genetic screening services (GSS), and pathology services. GSA services involve the sequencing and analysis of the DNA of humans, animals, plants, and microbes, to discover meaningful biological information. The company is engaged in providing GSS by developing its own range of genetic screening tests under the brand Dtect which screen human DNA for genetic markers related to diseases and health conditions. It derives the majority of its revenue from Pathology services.

Malaysian Genomics Resource Centre Bhd (XKLS:0155) Headlines

No Headlines